On November 1, 2022 Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), reported their collaboration with SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, for the development of a systems pharmacology model in multiple myeloma (Press release, Applied BioMath, NOV 1, 2022, View Source [SID1234622743]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In this collaboration, Applied BioMath is developing a model of SpringWorks’ investigational oral selective small molecule gamma secretase inhibitor (GSI), nirogacestat, in combination with an agent that targets B-cell maturation antigen (BCMA) for the treatment of multiple myeloma.
"Our goal is to lead the scientific understanding of the pharmacodynamic interactions between nirogacestat and BCMA-targeted agents in order to advance therapies more efficiently to help patients with multiple myeloma," said Todd Shearer, PhD, Vice President, Clinical Pharmacology at SpringWorks Therapeutics. "We are pleased to work with Applied BioMath given their expertise in building systems pharmacology models for biopharmaceutical companies and we look forward to working with them to further advance our BCMA efforts."
Applied BioMath offers software and services to help de-risk and accelerate drug R&D. Their solutions, which focus on quantitatively integrating knowledge about therapeutics with an understanding of its mechanism of action in the context of human disease mechanisms, are leveraged across the entire R&D spectrum from early research through to clinical trials. Their approach involves working with clients to develop the appropriate mathematical strategy for each unique project, with common strategies encompassing systems pharmacology, mechanistic modeling. bioinformatics, biosimulation, and clinical pharmacology.
"Applying mathematical and engineering approaches to translational medicine allows us to integrate knowledge about the therapeutic with an understanding of its mechanism of action in the context of human disease mechanisms," said John Burke, PhD, Co-founder, President and CEO at Applied BioMath. "This enables project teams developing therapeutics to answer more questions earlier and advance programs more efficiently."